Kite, a global biopharmaceutical company based in Santa Monica, California, a Gilead Company (Nasdaq: GILD), announced on Friday results from three new analyses for Yescarta(R) (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

The results included both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus(R) (brexucabtagene autoleucel) were presented at the 2024 European Hematology Association (EHA) Annual Congress in Madrid.

Results include a comparative analysis of real-world and clinical trial data (abstract P1425), which show higher manufacturing success rate and improved T-cell performance for Yescarta in second-line versus third-line plus treatment of R/R LBCL. Rapid and efficient manufacturing of CAR T-cell therapy can help reduce the time from leukapheresis to cell therapy infusion.

'We are committed to improving survival outcomes for people living with difficult-to-treat blood cancers,' said Ibrahim Elhoussieny, Kite vice president, Medical Affairs. 'These new data support the potential benefit of utilising Yescarta in earlier lines of treatment, both in terms of manufacturing success and product characteristics. Additional data support the safety and feasibility of administering CAR T-cell therapy in the outpatient setting. These data contribute to the body of evidence for efficient utilisation and delivery of Yescarta and Tecartus and further support our ambition for patients.'